November 10, 2020 10:40 AM ESTUpdated 11:18 AM

AstraZeneca, Amgen tout PhIII win for 'breakthrough' asthma drug, checking a blockbuster box that Dupixent didn't

A closely watched “breakthrough” asthma drug has hit all the right notes in a Phase III, AstraZeneca and Amgen say, paving the way to reach …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

As­traZeneca, Am­gen tout PhI­II win for 'break­through' asth­ma drug, check­ing a block­buster box that Dupix­ent did­n't